<p>Liminatus Pharma Inc. 收到了纳斯达克上市资格部门的通知，指出其未遵守多项纳斯达克上市规则。该公司在过去 30 个连续交易日内未能维持 5000 万美元的最低上市证券市场价值和 1500 万美元的最低公众持股市场价值。此外，Liminatus 还未满足另一项纳斯达克规则下的总资产和收入要求。尽管这些通知并不会立即影响公司的股票上市，但如果 Liminatus 无法在规定的时间内恢复合规，将面临退市风险。该公司正在积极努力解决这些缺陷。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Liminatus Pharma Inc. 于 2025 年 11 月 25 日通过美国证券交易委员会（Ref. ID: 0001104659-25-116049）运营的电子数据收集、分析和检索系统 EDGAR 发布了用于生成本新闻简报的原始内容，并对此信息的准确性承担全部责任。© 版权 2025 - 公共技术公司（PUBT）原始文档：这里</p>

LIMN

<p>Liminatus Pharma Inc. 因未遵守上市规则，未能维持所需的市场价值和资产/收入标准，面临纳斯达克退市的风险。该公司正在努力解决这些问题，以恢复合规</p>

<p>Liminatus Pharma Inc. has received notices from the Nasdaq Listing Qualifications Department indicating non-compliance with several Nasdaq listing rules. The company failed to maintain a minimum Market Value of Listed Securities of $50 million and a minimum Market Value of Publicly Held Shares of $15 million over the past 30 consecutive business days. Additionally, Liminatus does not meet requirements for total assets and revenue under another Nasdaq rule. Although these notifications do not immediately affect the company’s stock listing, Liminatus is at risk of delisting if it cannot regain compliance within the prescribed timeframe. The company is actively working to address these deficiencies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-116049), on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>
<div class="lb-trans"><p>Liminatus Pharma Inc. 收到了纳斯达克上市资格部门的通知，指出其未遵守多项纳斯达克上市规则。该公司在过去 30 个连续交易日内未能维持 5000 万美元的最低上市证券市场价值和 1500 万美元的最低公众持股市场价值。此外，Liminatus 还未满足另一项纳斯达克规则下的总资产和收入要求。尽管这些通知并不会立即影响公司的股票上市，但如果 Liminatus 无法在规定的时间内恢复合规，将面临退市风险。该公司正在积极努力解决这些缺陷。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Liminatus Pharma Inc. 于 2025 年 11 月 25 日通过美国证券交易委员会（Ref. ID: 0001104659-25-116049）运营的电子数据收集、分析和检索系统 EDGAR 发布了用于生成本新闻简报的原始内容，并对此信息的准确性承担全部责任。© 版权 2025 - 公共技术公司（PUBT）原始文档：这里</p>
</div>

Liminatus Pharma 因违反市值规则而面临被纳斯达克退市的风险